Navigation Links
Combination therapy shows potent tumor growth inhibition in preclinical studies
Date:11/13/2011

SAN FRANCISCO Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

"These preclinical findings suggest that combining REGN910 (SAR307746) and aflibercept in the clinic could be an attractive approach for future clinical research," said Alshad S. Lalani, Ph.D., director of strategic oncology development at Regeneron Pharmaceuticals Inc. in Tarrytown, N.Y. "The rationale is that inhibition of tumor angiogenesis by combining antiangiogenesis treatments could translate into more potent and durable antitumor responses than those observed with single-agent therapy."

In this preclinical mouse study, researchers from Regeneron and BC Cancer Agency in Vancouver, British Columbia, Canada, monitored how REGN910 and aflibercept blocked vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), which are critical growth factors for tumor angiogenesis, or blood vessel formation.

REGN910 is a fully human monoclonal antibody discovered using Regeneron VelocImmune antibody technology that binds and inhibits Ang2. Aflibercept is a fully human fusion protein that binds all forms of VEGF-A, as well as VEGF-B and placental growth factor. REGN910 and aflibercept are being developed by Regeneron and Sanofi.

In addition, researchers performed tissue analyses to monitor the number of tumor blood vessels, tumor hypoxia (oxygen deprivation), tumor cell death and tumor perfusion.

"When used alone in animal studies, both REGN910 and aflibercept blocked tumor angiogenesis and growth; however, the combination of the two led to increased tumor hypoxia and consequently to the death of a large percentage of the tumor cells," Lalani said. "Consistent with its ability to promote rapid and widespread tumor cell death in histology, the combination treatment inhibited tumor growth to a significantly greater extent than the single agents in multiple tumor models colorectal, mammary and prostate. In particular, it caused dramatic tumor regression in the colorectal tumor models. Importantly, no visible evidence of toxicities or enhanced body weight loss was observed following the combination treatment."

In ongoing animal studies, Lalani and colleagues are studying the reasons behind the results with the combined therapy. They are also investigating biomarkers that will allow them to monitor the combination therapy treatment effect and/or to identify which tumors are most likely to respond to treatment.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Manchesters first step to perfect drug combinations
2. Combination HPV diagnostic test for head and neck cancer outperformed other tests
3. Novel drug combination offers therapeutic promise for hard-to-treat cancers
4. The machinery for recombination is part of the chromosome structure
5. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
6. Unique gene combinations control tropical maize response to day lengths
7. A drug combination extends survival in refractory lung cancer patients
8. Microbubble-delivered combination therapy eradicates prostate cancer in vivo
9. Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
10. Killing drug-resistant melanoma requires combination therapy
11. Combination therapy reduced HER2-positive breast cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling ... (CSO) that provides biopharma companies the experience, expertise, ... and deploy outsourced sales teams. Created in concert ... addresses both the strategic and tactical needs of ... sales solutions through both personal and non-personal promotion. ...
(Date:2/11/2016)... BioInformant announces the February 2016 release of its ... and Technologies – Market Size, Segments, Trends, and Projections ... The first and only market research firm ... more than a decade of historical information on all ... type. This powerful 175 page global strategic report contains ...
(Date:2/10/2016)... WASHINGTON , February 10, 2016 Early-career ... , Peru , Uganda ... their life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are ... sciences and epidemiology. They are also celebrated for mentoring young women scientists ...
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
Breaking Biology Technology: